Authors
Latest:
Dr Mathews on Maintenance Olaparib in Ovarian CancerCara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.
Latest:
Dr. Sridhar on the Long-Term Data from the JAVELIN Bladder 100 Trial in Advanced Urothelial CarcinomaSrikala Sridhar, MD, MSc, FRCPC, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 in patients with advanced urothelial carcinoma.
Latest:
Current Treatment Options for Patients with Steroid-Refractory Acute GVHDClosing her discussion, Dr Pashna Munshi reviews recent data on the available treatment options for patients with steroid-refractory acute GVHD.
Latest:
Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast CancerMadhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.
Latest:
Trainees Deserve Better FeedbackFeedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.
Latest:
Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer ModelsAyesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.
Latest:
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AMLThe prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Latest:
NGC-Cap Demonstrates Preliminary Efficacy in Stage III/IV GI CancerNext generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.
Latest:
The US Oncology Network Extends Its Reach into Tennessee with The Addition of Nashville Oncology AssociatesThe Network continues its strong growth trajectory and its mission to enhance community-based cancer care.
Latest:
Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCLMuhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.
Latest:
Dr Stokes on Radiation Vs Surgery in HPV+ OPSCCWilliam (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.
Latest:
Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and ClassificationChristopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian CancerPaul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.
Latest:
Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal CancerI-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.
Latest:
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPCNeil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Latest:
Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian CancerKala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.
Latest:
Seeing Medicine Through the Eye of an ArtistFor many people who go into research, there’s a moment somewhere along the way that is immediately addictive and makes you want to experience that over and over again.
Latest:
Dr Di Meo on the Rationale for Developing LILRB4–Directed CAR T-Cell Therapy in Multiple MyelomaFrancesco Di Meo, PhD, discusses the rationale for targeting LILRB4 through CAR T-cell therapy in multiple myeloma.
Latest:
Dr Leslie on the Management of CAR T-Cell Therapy Toxicities in LBCLLori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.
Latest:
Dr Pantin on the Evolving Treatment Paradigm in PNHJeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.
Latest:
Future Treatment Landscape of AMLCorey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.
Latest:
Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal ResectionRosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.
Latest:
Dr. Dahiya on Long-Term, Real-World Follow-Up of Axi-Cel in LBCLSaurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.
Latest:
Dr. Lwin on Patient Selection for LEAP-005 Study in CRC, Biliary Tract Cancer, and MoreZarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.
Latest:
When Lung Cancer Took One Lung and COVID Took the Other, a Chicago Police Captain Was Left With Only One Option for SurvivalSeeking a second opinion, Arthur “Art” Gillespie turned to Northwestern Medicine for a life-saving double-lung transplant procedure.
%201%20(1)-Recovered%20copy.jpg?fit=crop&auto=format)
%201%20(1)-Recovered%20copy.jpg?fit=crop&auto=format)
